-
公开(公告)号：US20230345919A1
公开(公告)日：2023-11-02
申请号：US18320789
申请日：2023-05-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Alexander O. Mujica , Viktoria Gusarova , Cheng Wang , Christos Kyratsous , Terra Potocky , Katherine Cygnar , Joel H. Martin
IPC: A01K67/027 , A61K49/00 , C07K14/705 , C12N5/071 , C12N5/10
CPC classification number: A01K67/0278 , A61K49/0008 , C07K14/7056 , C12N5/0608 , C12N5/10 , A01K2207/15 , A01K2217/072 , A01K2227/105
Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
-
Patent Agency Ranking
公开(公告)号：US20210107974A1
公开(公告)日：2021-04-15
申请号：US17113642
申请日：2020-12-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Scott Walsh , Terra Potocky , Daniel Dix , Renuka Sivendran
Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
-
公开(公告)号：US20200154684A1
公开(公告)日：2020-05-21
申请号：US16625168
申请日：2018-06-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Alexander O. Mujica , Viktoria Gusarova , Cheng Wang , Christos Kyratsous , Terra Potocky , Katherine Cygnar , Joel Martin
IPC: A01K67/027 , A61K49/00 , C07K14/705
Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
-
公开(公告)号：US12037411B2
公开(公告)日：2024-07-16
申请号：US17051987
申请日：2019-04-29
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Andres Perez Bay , Julian Andreev , Terra Potocky , Xunbao Duan
CPC classification number: C07K16/32 , A61K47/6849 , A61K47/6879 , A61P35/00 , A61K2039/505
Abstract: The protein known as human epidermal growth factor 2 (HER2) is expressed in breast cancer cells and its expression is correlated with aggressive tumor growth. The present invention provides novel full-length human (IgG) antibodies that bind to human HER2 (monospecific antibodies) or to APLP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both HER2 and APLP2 and mediate internalization and degradation of HER2 via the APLP2 complex in the presence of HER2-expressing tumors. Described are bispecific antigen-binding molecules and ADCs comprising a first antigen-binding domain that specifically binds human APLP2, and a second antigen-binding domain that specifically binds human HER2. The described bispecific ADCs are capable of inhibiting the growth of certain tumors expressing HER2 and may be useful for the treatment of breast cancer and disorders in which targeting a therapeutic agent to HER2-expressing tumor cell is desirable and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of breast cancers, including breast cancers having a IHC2+ classification. The present invention also includes anti-HER2 antibody drug conjugates which inhibit tumor growth in vivo.
-
公开(公告)号：US11696572B2
公开(公告)日：2023-07-11
申请号：US16625168
申请日：2018-06-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Alexander O. Mujica , Viktoria Gusarova , Cheng Wang , Christos Kyratsous , Terra Potocky , Katherine Cygnar , Joel H. Martin
IPC: A01K67/027 , A61K49/00 , C07K14/705 , C12N5/071 , C12N5/10
CPC classification number: A01K67/0278 , A61K49/0008 , C07K14/7056 , C12N5/0608 , C12N5/10 , A01K2207/15 , A01K2217/072 , A01K2227/105
Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.
-
公开(公告)号：US20190010222A1
公开(公告)日：2019-01-10
申请号：US16135953
申请日：2018-09-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Scott Walsh , Terra Potocky , Daniel Dix , Renuka Sivendran
IPC: C07K16/22 , A61K47/22 , A61J1/06 , A61K39/395 , A61M5/315 , A61K47/26 , A61J1/14 , A61K47/18 , A61K47/12 , A61K39/00
Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
